Home>Topics>>InterMune Gearing Up For Another Round With The FDA
InterMune Gearing Up For Another Round With The FDA
Long Investing Ideas from Seeking Alpha
Thu, 29 Nov 2012
By Brian L. Wilson : After spending the last few months in a well-defined trading range of $8-10 per share, the pulmonary fibrosis drug development company InterMune (NASDAQ: ITMN ) has settled right in the middle (at $9/share) as investors wait for more news on its flagship product, pirfenidone. ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.